💥 Gate Square Event: #PostToWinTRUST 💥
Post original content on Gate Square related to TRUST or the CandyDrop campaign for a chance to share 13,333 TRUST in rewards!
📅 Event Period: Nov 6, 2025 – Nov 16, 2025, 16:00 (UTC)
📌 Related Campaign:
CandyDrop 👉 https://www.gate.com/announcements/article/47990
📌 How to Participate:
1️⃣ Post original content related to TRUST or the CandyDrop event.
2️⃣ Content must be at least 80 words.
3️⃣ Add the hashtag #PostToWinTRUST
4️⃣ Include a screenshot showing your CandyDrop participation.
🏆 Rewards (Total: 13,333 TRUST)
🥇 1st Prize (1 winner): 3,833
The US stock-listed Ethereum treasury company Propanc Biopharma announced the acquisition of the undervalued DAT entity.
According to a report by GLOBE NEWSWIRE on November 4, Deep Tide TechFlow announced that Nasdaq-listed biopharmaceutical company Propanc Biopharma (PPCB) has initiated a strategic acquisition plan, targeting the acquisition of the digital asset treasury (DAT) company with a market capitalization below its net asset value.
The company's management believes that the acquisition of undervalued DAT entities will help strengthen the balance sheet, achieve asset diversification, and create long-term shareholder value. These DAT companies often hold substantial reserves of mainstream digital assets such as Bitcoin and Ethereum on their balance sheets.
CEO James Nathanielsz stated that this is a strategic diversification initiative aimed at unlocking value for shareholders while continuing to advance the innovative oncology pipeline. The company's board and executive team are evaluating potential acquisition targets.
Previously, Propanc Biopharma announced plans for an acquisition of 100 million US dollars in Ethereum.